BIAL enters the US and acquires “promising” Parkinson’s disease programmes

News

Author: Simge Eva DoganPublished: 8 October 2020

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

BIAL Parkinson's research and development department

Portugal-based pharmaceutical company BIAL has launched a new research centre, BIAL Biotech, in Massachusetts, US, which will focus on genetically defined Parkinson’s disease.

BIAL has also announced that it has acquired the Parkinson’s disease research programmes of Lysosomal Therapeutics Inc, as well as its research and development team and clinical programme for LTI-291 – a therapy designed to treat a genetic form of the condition.

António Portela, executive president of BIAL, said: “Our entry into the US with the creation of BIAL Biotech and the acquisition of the promising programmes from LTI, is a decisive step towards the fulfilment of our mission to contribute to improving the quality of life of people worldwide.

“The development of this new research centre in the US, is a landmark of enormous relevance for us. We are investing in science and research, through our direct presence in one of the most important research hubs in the world and in one of the most promising areas of medicine.”

Lead image: research and development department at BIAL


Read more:

Could a single daily pill deliver Parkinson’s medication?

New tool could support “faster diagnosis” of Parkinson’s disease psychosis

Go Back

Share this story

Comments


Related articles


Global update

Neurologists should ‘speak up’ about Covid vaccines for people with Parkinson’s, says study

Breaking barriers to vaccination in the Parkinson’s disease community

READ MORE
MarianBasPaula lead

Europe

Leading MEP declares Parkinson’s “a European priority issue”

Campaigners advocate for better EU policy towards Parkinson’s

READ MORE

Special reports

Reimagining Parkinson’s healthcare: a patient-focused plan

A recent report suggests eight ways to improve Parkinson’s treatment

READ MORE